Appeal No. 2005-1164 Page 10
Application No. 09/721,131
Accordingly, there is no evidence on this record supporting appellant’s asserted
utility.
We recognize appellant’s assertion (Brief, page 10), “that treating HIV
infection was once considered an inherently unbelievable undertaking, but since
then, treatments for HIV infection have gained acceptance, and both AZT
(zidovudine) and 3TC (lamivudine) are recognized as effective for treating HIV
infection.” Both AZT and 3TC function by blocking reverse transcription. See
Goldman, bridging paragraph, pages 1934-1935. There is no evidence on this
record that NaCl in the amount set forth in appellant’s claim would block reverse
transcription of HIV RNA. Further, as explained in the Merck brochure entitled
“Livin’ It” the drug CRIXIVAN® is a protease inhibitor which functions to “stop the
protease enzyme from cutting protein chains into the smaller pieces that are
needed for new virions.” There is no evidence on this record that NaCl in the
amount set forth in appellant’s claim would act as a protease inhibitor.
9 According to appellant this brochure illustrates (1) the “size difference” between an HIV particle
and a T-cell (Brief, page 6), and (2) “how HIV infects a person” (Brief, page 8).
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: November 3, 2007